XM does not provide services to residents of the United States of America.

Walgreens to shut 1,200 stores as CEO Wentworth seeks turnaround



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Walgreens to shut 1,200 stores as CEO Wentworth seeks turnaround</title></head><body>

Walgreens edges past Wall St's lowered Q4 profit estimates

Forecasts FY adj EPS of $1.40-$1.80, vs estimate of $1.73

Shares gain 5% premarket

Adds analyst comment in paragraph 3, updates share movement in paragraph 2, add graphic

By Manas Mishra

Oct 15 (Reuters) -Walgreens Boots Alliance WBA.O said on Tuesday it would shut 1,200 stores over the next three years as new CEO Tim Wentworth plots a turnaround at the struggling pharmacy chain operator hit by sluggish consumer spending and low drug reimbursement rates.

The company also narrowly beat Wall Street's lowered estimates for fourth-quarter adjusted profit, and forecast fiscal-year earnings that were mostly in line with expectations.

Its shares jumped 5.4% to $9.50 in premarket trading.

"At first blush, (the forecast) looks better than worst-case scenario," said Leerink Partners analyst Michael Cherny, adding that Walgreens continues to be buffeted by macro challenges that did not abate in the quarter.

Pharmacy chains are facing multiple challenges as consumers avoid high-priced grocery items and pressures mount on payments they receive from drug middlemen for filling prescriptions.

As a result, Walgreens' stock is trading near 30-year lows and down 65% this year, making it the worst performeron the S&P 500 index .SPX.



CEO Wentworth has unveiled a series of changes since taking on the top job last year, including the removal of multiple mid-level executives and a $1 billion cost-cutting program.

"This turnaround will take time, but we are confident it will yield significant financial and consumer benefits over the long term," said Wentworth in a statement.

The closures were announced in June but the company had not disclosed the number of affected stores at that time. It had over 8,000 stores in the United States as of Aug. 31 last year.

In the fourth quarter of its fiscal year 2024, Walgreens recorded goodwill impairmentcharges related to its homecare unit CareCentrixand equity investmentsin China. It reported a loss of $3 billion on a reported basis, versus $180 million a year ago.

Excluding those items and other charges, the company earned 39 cents per share. Analysts had expected a profit of 36 cents per share, according to data compiled by LSEG.

For fiscal 2025, Walgreens said it expects adjusted earnings of $1.40 to $1.80 per share, versus estimates of $1.73 per share.


Walgreens is the worst-performing S&P 500 constituent in 2024 https://tmsnrt.rs/4eKBQUi


Reporting by Manas Mishra and Sneha S K in Bengaluru; Editing by Saumyadeb Chakrabarty and Maju Samuel

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.